Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | PRF1 | P14222 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 4/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27354572 | 0.82 | MAPT (0.49) | ALDH1A1KDM4EPKMMAPTHSD17B10 | |
| SCHEMBL6087830 | 0.73 | MAPT (0.52) | ALDH1A1KDM4EPKMMAPTPRF1 | |
| SCHEMBL5365075 | 0.72 | PRF1 (0.68) | ALDH1A1KDM4EPKMMAPTPRF1 | |
| SCHEMBL27354574 | 0.72 | MAPT (0.43) | ALDH1A1KDM4EPKMMAPTHSD17B10 | |
| SCHEMBL30696747 | 0.72 | MAPT (0.43) | ALDH1A1KDM4EPKMMAPTHSD17B10 | |
| SCHEMBL30696827 | 0.71 | MAOA (0.43) | KDM4EMAPTHSD17B10GAAMAOA | |
| SCHEMBL26994676 | 0.70 | MAOA (0.59) | ALDH1A1KDM4EMAPTGAAMAOA | |
| SCHEMBL27356784 | 0.69 | BCHE (0.42) | KDM4EMAPTHSD17B10GAAMAOA | |
| SCHEMBL286421 | 0.69 | CYP3A4 (0.42) | ALDH1A1KDM4EPKMMAPTGAA | |
| SCHEMBL21070577 | 0.67 | STAT3 (0.62) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543439-A2 | NRF2 PROTEIN DEGRADERS | Ganymede Oncology, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2024006742-A2 | NRF2 PROTEIN DEGRADERS | DRACEN PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |